Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under…
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline Bristol Myers Squibb announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society…
Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026 Flatiron Health announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 – June 2, 2026, in Chicago, Illinois. Flatiron’s high-quality…
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present multiple abstracts at the 2026 American Society of…
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Savara Inc. a clinical stage biopharmaceutical company focused on rare respiratory diseases,…
Flatiron Health Launches Flatiron Telescope, a New AI Platform Delivering Oncology Insights in Minutes Flatiron Health announced the launch of Flatiron Telescope, a next-generation AI-powered platform designed to help life sciences teams and researchers find the right patients faster, assess study…
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology Blank Bio, an applied AI research lab training foundation models for RNA, announced the closing of a $7.2 million seed financing and…
Sustained Therapeutics Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual Meeting Sustained Therapeutics, Inc. a clinical-stage urologic therapeutics company advancing differentiated therapies for underserved conditions, today presented additional data from its…
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer Bayer announced that the U.S. Food and Drug Administration (FDA) has granted HYRNUO® (sevabertinib) Priority Review status for…
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead Turn Therapeutics Inc. a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, announced the appointment of Stephen M. Hahn,…
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing Scribe Therapeutics, Inc. a biotechnology company engineering purpose-built CRISPR technologies to reshape the treatment of disease by…
Bojangles Foundation Raises More Than $650,000 Through Heart-Shaped Biscuits & Round-Up Campaign to Support Pediatric Heart Care and Research For the second year in a row, Bojangles and The Bojangles Foundation partnered with NFL legend Greg Olsen and The HEARTest…